Stimulants

Concerta - Drug Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2019

The "Concerta - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Concerta - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Concerta Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • A review of the Concerta, based on information derived from company and industry-specific sources
    Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification

Worldwide Markets for Small Molecule Drug Discovery to 2026: Key Analyses & Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, January 18, 2019

The "Small Molecule Drug Discovery - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Small Molecule Drug Discovery - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • According to this report, the Global Small Molecule Drug Discovery Market is expected to grow at a CAGR of 8.5% during the forecast period.
  • Some of the factors such as rise in drug discovery and development and rising usage of these drugs in the treatment of chronic diseases are driving the market growth.
  • Based on geography, North America is anticipated to be one of the leading regions contributing to the global market during the forecast period.

Definitive Agreement Marks Milestone for Alternative Nicotine Delivery Options

Retrieved on: 
Wednesday, January 16, 2019

And Imperial Brands PLC ADR (OTC:IMBBF) (OTC:IMBBY) has established a stake in a cannabis biotech company as it explores the options for this alternative drug.

Key Points: 
  • And Imperial Brands PLC ADR (OTC:IMBBF) (OTC:IMBBY) has established a stake in a cannabis biotech company as it explores the options for this alternative drug.
  • The program will include a comprehensive series of clinical investigations of oral forms of nicotine delivery, utilizing the company's patented DehydraTECH technology.
  • The bioscience potential for nicotine delivery cannot be ignored, but this strategic partnership is about more than big money for big innovations.
  • The aim of the agreement is to create a more socially acceptable and less disruptive way to consume nicotine.

Definitive Agreement Marks Milestone for Alternative Nicotine Delivery Options

Retrieved on: 
Wednesday, January 16, 2019

And Imperial Brands PLC ADR (OTC:IMBBF) (OTC:IMBBY) has established a stake in a cannabis biotech company as it explores the options for this alternative drug.

Key Points: 
  • And Imperial Brands PLC ADR (OTC:IMBBF) (OTC:IMBBY) has established a stake in a cannabis biotech company as it explores the options for this alternative drug.
  • The program will include a comprehensive series of clinical investigations of oral forms of nicotine delivery, utilizing the company's patented DehydraTECH technology.
  • The bioscience potential for nicotine delivery cannot be ignored, but this strategic partnership is about more than big money for big innovations.
  • The aim of the agreement is to create a more socially acceptable and less disruptive way to consume nicotine.

Cingulate Therapeutics to Present at Biotech Showcase™ 2019 in San Francisco

Retrieved on: 
Monday, January 7, 2019

Cingulate is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults.

Key Points: 
  • Cingulate is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults.
  • The Company has completed a Proof of Concept Phase I clinical trial and plans to implement the full clinical plan for both CTx-1301 and CTx-1302 in 2018.
  • Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2018 and will pursue approval via the accelerated 505(b)(2) regulatory pathway.
  • The company has offices in Kansas City, KS and Morristown, NJ.

Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Retrieved on: 
Friday, December 21, 2018

The updated Prescription Drug User Fee Act (PDUFA)goal date is now March 20, 2019.

Key Points: 
  • The updated Prescription Drug User Fee Act (PDUFA)goal date is now March 20, 2019.
  • "We are committed to addressing unmet needs in sleep medicine and look forward to offering solriamfetol as a meaningful treatment option for patients living with excessive daytime sleepiness associated with narcolepsy or OSA."
  • Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) in development for treatment of excessive sleepiness in adult patients with narcolepsy, OSA, and Parkinson's disease.
  • In 2014,Jazz Pharmaceuticals acquired a license to develop and commercialize solriamfetol from Aerial Biopharma.Jazz Pharmaceuticalshas worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions inAsia.

Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Retrieved on: 
Friday, December 21, 2018

The updated Prescription Drug User Fee Act (PDUFA)goal date is now March 20, 2019.

Key Points: 
  • The updated Prescription Drug User Fee Act (PDUFA)goal date is now March 20, 2019.
  • "We are committed to addressing unmet needs in sleep medicine and look forward to offering solriamfetol as a meaningful treatment option for patients living with excessive daytime sleepiness associated with narcolepsy or OSA."
  • Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) in development for treatment of excessive sleepiness in adult patients with narcolepsy, OSA, and Parkinson's disease.
  • In 2014,Jazz Pharmaceuticals acquired a license to develop and commercialize solriamfetol from Aerial Biopharma.Jazz Pharmaceuticalshas worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions inAsia.

Global Narcolepsy Market and Competitive Landscape 2014-2023 - Estimate and Forecast Market Size and Drug Sales

Retrieved on: 
Monday, October 29, 2018

Table 1: Narcolepsy Phase 3 Clinical Trials, Global, 2018

Key Points: 
  • Table 1: Narcolepsy Phase 3 Clinical Trials, Global, 2018
    Table 2: Narcolepsy Phase 2 Clinical Trials, Global, 2018
    Table 3: Narcolepsy Phase 1 Clinical Trials, Global, 2018
    Table 4: Narcolepsy Prevalence by G7 Countries, 2017 - 2023
    Table 5: Marketed Products for Narcolepsy in US, 2017
    Table 9: Marketed Products for Narcolepsy in Germany, 2017
    Table 13: Marketed Products for Narcolepsy in France, 2017
    Table 17: Marketed Products for Narcolepsy in Italy, 2017
    Table 21: Marketed Products for Narcolepsy in Spain, 2017
    Table 25: Marketed Products for Narcolepsy in UK, 2017
    Table 31: Marketed Products for Narcolepsy in Japan, 2017
    Figure 1: Narcolepsy Pipeline by Phase (%), Global, 2018
    Figure 2: Narcolepsy Prevalence by G7 Countries, 2017 - 2023
    ResearchAndMarkets.com is the world's leading source for international market research reports and market data.
  • We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
  • Did you know that we also offer Custom Research?
  • Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Global Cocaine Dependence Market and Competitive Landscape Report 2018

Retrieved on: 
Friday, October 26, 2018

The "Global Cocaine Dependence Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cocaine Dependence Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • The latest research Global Cocaine Dependence Market and Competitive Landscape - 2018, provides comprehensive insights into Cocaine Dependence pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Cocaine Dependence overview with definitions, symptoms, etiology, diagnosis, treatment options; Cocaine Dependence pipeline insights covering late stage clinical trials pipeline; Cocaine Dependence prevalence trends by countries; Cocaine Dependence market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Cocaine Dependence pipeline: Find out the drugs in clinical trials for Cocaine Dependence by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Cocaine Dependence epidemiology: Find out the prevalence of Cocaine Dependence by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Cocaine Dependence products: Identify key products marketed and prescribed for Cocaine Dependence by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Cocaine Dependence market size: Find out the market size for Cocaine Dependence drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Cocaine Dependence drug sales: Find out the sales of Cocaine Dependence drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Cocaine Dependence drugs sales forecast: Sales forecast for Cocaine Dependence drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Cocaine Dependence market share analysis: Find out the market shares of Cocaine Dependence drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?

Global Legal Cocaine Markets 2022: Market to Grow at a CAGR of 5.17% - Focus on Surgical & Non-Surgical Applications

Retrieved on: 
Tuesday, October 9, 2018

The "Global Legal Cocaine Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Legal Cocaine Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Legal Cocaine Market to grow at a CAGR of 5.17% during the period 2018-2022.
  • Global Legal Cocaine Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts.
  • According to the report, one driver influencing this market is the growing demand for pharmaceutical-grade cocaine.